Group 1 - The board meeting of Qingdao Weilan Biological Co., Ltd. was held on August 27, 2025, with all five directors present, ensuring compliance with relevant regulations [1][2] - The meeting's resolutions were deemed legal and effective, following the procedures outlined in the Company Law of the People's Republic of China and the company's articles of association [1] - The board approved the special report on the use of raised funds, with unanimous support from all directors present [2] Group 2 - The meeting was convened after prior approval from the company's audit committee, indicating a structured decision-making process [2] - All votes during the meeting were in favor, with no dissenting or abstaining votes recorded [2] - Detailed information regarding the half-year report and the special report on fund usage can be found on the Shanghai Stock Exchange website [1][2]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-037 青岛蔚蓝生物股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》及相关格式指引的规定，青岛蔚蓝生物股份有限公 司（以下简称"公司"）现将 2025 年半年度募集资金存放与实际使用情况专项说 明如下： 一、募集资金基本情况 （一）首次公开发行募集资金 经中国证券监督管理委员会证监许可[2018]1961 号文核准，公司向社会公 众公开发行人民币普通股(A 股)股票 3,866.70 万股，发行价为每股人民币 10.19 元，共计募集资金 394,016,730.00 元，扣除各项发行费用后，实际募集资金净 额为人民币 347,440,291.00 元。上述募集资金已于 2019 年 1 月 9 日到位，已经 瑞华会计师事务所（特殊普通合伙）验证，并由其出具《验资报告》(瑞华验字 [2019]37110002 号)。公司对募集资金实行专户存储。 明细 金 ...

Core Viewpoint - Qingdao Weilan Biological Co., Ltd. disclosed its major operational data for Q2 2025, highlighting significant revenue figures and changes in distributor numbers, which provide insights into the company's performance and market dynamics [1]. Group 1: Operational Performance - The total revenue for Q2 2025 amounted to CNY 255,554,845.37, with enzyme preparations contributing CNY 118,822,845.82 and micro-ecological preparations contributing CNY 62,179,855.65 [1]. - Direct sales accounted for CNY 171,922,085.69, while distribution sales totaled CNY 83,632,759.68 [1]. - Domestic sales reached CNY 224,210,819.54, while overseas sales were CNY 31,344,025.83 [1]. Group 2: Distributor Changes - The total number of distributors increased from 545 to 636 during the reporting period, indicating a growth in the distribution network [1]. - In Northeast China, the number of distributors rose from 31 to 38, while in North China, it increased from 60 to 76 [1]. - The East China region saw a significant increase from 304 to 331 distributors, while South China had a slight increase from 50 to 55 [1].

Core Viewpoint - The company, Qingdao Vland Biotech Group Co., Ltd., is set to hold a half-year performance briefing on September 4, 2025, to discuss its operational results and financial status for the first half of 2025 [1][2]. Group 1: Meeting Details - The meeting will take place on September 4, 2025, from 9:00 AM to 10:00 AM [1][2]. - It will be held at the Shanghai Stock Exchange Roadshow Center, accessible via the website: http://roadshow.sseinfo.com/ [1][2]. - The format of the meeting will be an interactive online session [1][2]. Group 2: Participation Information - Investors can submit questions from August 28, 2025, to September 3, 2025, before 4:00 PM through the Roadshow Center's "Question Pre-collection" section or via the company's email [2][3]. - The company will address commonly asked questions during the briefing [2][3]. Group 3: Attendees - Key attendees include the Chairman and General Manager, Chen Gang; the Director and Chief Financial Officer, Qiao Piyuan; the Secretary of the Board, Jiang Yong; and independent directors Wang Jing and Lin Yingtian [2]. Group 4: Contact Information - For inquiries, investors can contact Jiang Yong at phone number 0532-88978071 or via email at vland@vlandgroup.com [3]. Group 5: Post-Meeting Access - After the meeting, investors can view the meeting's proceedings and main content on the Shanghai Stock Exchange Roadshow Center website [3].

Core Insights - The company reported a revenue of 652 million yuan for the first half of 2025, representing a year-on-year increase of 7.05% [1] - The net profit attributable to shareholders decreased by 8.98% to 26.72 million yuan [1] - The net profit excluding non-recurring items was 16 million yuan, showing a year-on-year growth of 4.17% [1] - The basic earnings per share stood at 0.11 yuan [1]

证券日报网讯 8月27日晚间，蔚蓝生物发布公告称，2025年半年度公司实现营业收入652，193，328.83 元，同比增长7.05%；归属于上市公司股东的净利润为26，716，293.11元，同比下降8.98%。 （编辑 何成浩） ...

证券日报网讯 8月27日晚间，蔚蓝生物发布公告称，公司第五届监事会第十一次会议审议通过了《关于 及摘要的议案》《关于的议案》。 （文章来源：证券日报） ...

证券日报网讯 8月27日晚间，蔚蓝生物发布公告称，公司第五届董事会第十九次会议审议通过了《关于 及摘要的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - Youyou Food achieved a net profit of 108 million yuan in the first half of 2025, a year-on-year increase of 42.47%, with a revenue of 771 million yuan, up 45.59% [1] - Keda achieved a net profit of 255 million yuan, a year-on-year increase of 16.49%, with a revenue of 2.163 billion yuan, up 14.35% [1] - North Navigation turned a profit with a net profit of 116 million yuan, achieving a revenue of 1.703 billion yuan, a year-on-year increase of 481.19% [1][2] Group 2 - China Satellite Communication reported a net profit of 181 million yuan, a year-on-year decrease of 55.59%, with a revenue of 1.221 billion yuan, up 6.33% [3] - Huqin Technology achieved a net profit of 1.889 billion yuan, a year-on-year increase of 46.3%, with a revenue of 83.939 billion yuan, up 113.06% [4] - Huasen Lithium reported a net loss of 72.739 million yuan, with a revenue of 350 million yuan, up 72.02% [4] Group 3 - Putailai achieved a net profit of 1.055 billion yuan, a year-on-year increase of 23.03%, with a revenue of 7.088 billion yuan, up 11.95% [5] - Suochen Technology reported a net loss of 45.698 million yuan, with a revenue of 57.351 million yuan, up 10.82% [5] - Canqin Technology achieved a net profit of 51.912 million yuan, a year-on-year increase of 51.94%, with a revenue of 287 million yuan, up 52.76% [6] Group 4 - Hengtong achieved a net profit of 99.3648 million yuan, a year-on-year increase of 38.86%, with a revenue of 669 million yuan, down 44.66% [6] - Sanan Optoelectronics reported a net profit of 176 million yuan, a year-on-year decrease of 4.24%, with a revenue of 8.987 billion yuan, up 17.03% [7] - New Dairy achieved a net profit of 397 million yuan, a year-on-year increase of 33.76%, with a revenue of 5.526 billion yuan, up 3.01% [8] Group 5 - Yiling Pharmaceutical achieved a net profit of 669 million yuan, a year-on-year increase of 26.03%, with a revenue of 4.040 billion yuan, down 12.26% [10] - Baosteel achieved a net profit of 4.879 billion yuan, a year-on-year increase of 7.36%, with a revenue of 151.372 billion yuan, down 7.28% [12] - Feikai Materials achieved a net profit of 217 million yuan, a year-on-year increase of 80.45%, with a revenue of 1.462 billion yuan, up 3.8% [13] Group 6 - Lier Chemical achieved a net profit of 271 million yuan, a year-on-year increase of 191.21%, with a revenue of 4.507 billion yuan, up 35.36% [15] - Shaanxi Coal achieved a net profit of 7.638 billion yuan, a year-on-year decrease of 31.18%, with a revenue of 779.83 billion yuan, down 14.19% [16] - Dongfang Materials reported a net profit of 654,400 yuan, a year-on-year decrease of 88.48%, with a revenue of 174 million yuan, down 5.06% [18] Group 7 - Blue Sky Bio achieved a net profit of 26.7163 million yuan, a year-on-year decrease of 8.98%, with a revenue of 652 million yuan, up 7.05% [19] - Shanghai Jiubai achieved a net profit of 23.7897 million yuan, a year-on-year increase of 0.24%, with a revenue of 45.0535 million yuan, down 1.09% [20] - Two Sides Needle reported a net loss of 5.0842 million yuan, with a revenue of 522 million yuan, up 1.02% [21] Group 8 - Shanghai Yashi achieved a net profit of 20.3263 million yuan, a year-on-year increase of 42.56%, with a revenue of 2.044 billion yuan, up 56.75% [23] - Bayi Steel reported a net loss of 697 million yuan, with a revenue of 8.733 billion yuan, down 6.73% [25] - Hongrun Construction plans to repurchase shares worth between 150 million and 300 million yuan [27] Group 9 - Kaile achieved a net profit of 10.9193 million yuan, a year-on-year increase of 280.42%, with a revenue of 137 million yuan, down 17.89% [28] - Jingda achieved a net profit of 306 million yuan, a year-on-year increase of 6.03%, with a revenue of 11.856 billion yuan, up 14.28% [29] - Blue Light Marker reported a net profit of 96.4427 million yuan, a year-on-year decrease of 47.33%, with a revenue of 32.36 billion yuan, up 4.87% [30] Group 10 - KOTAI Power achieved a net profit of 23.994 million yuan, a year-on-year increase of 35.52%, with a revenue of 711 million yuan, up 49.51% [33] - Bo Rui Data reported a net loss of 26.1918 million yuan, with a revenue of 70.1997 million yuan, up 5.19% [34] - Jiuzhoutong achieved a net profit of 1.446 billion yuan, a year-on-year increase of 19.7%, with a revenue of 81.106 billion yuan, up 5.10% [37] Group 11 - Aier Eye Hospital achieved a net profit of 2.051 billion yuan, a year-on-year increase of 0.05%, with a revenue of 11.507 billion yuan, up 9.12% [39] - Nandu Property achieved a net profit of 130 million yuan, a year-on-year increase of 532.87%, with a revenue of 914 million yuan, up 2.75% [41] - Weiyuan reported a net loss of 168 million yuan, with a revenue of 4.601 billion yuan, up 1.82% [42] Group 12 - Zhongke Chuangda achieved a net profit of 158 million yuan, a year-on-year increase of 51.84%, with a revenue of 3.299 billion yuan, up 37.44% [43] - Zhongjuxin reported a net profit of 8.1377 million yuan, a year-on-year decrease of 64.57%, with a revenue of 567 million yuan, up 20.40% [44] - Inspur Information achieved a net profit of 799 million yuan, a year-on-year increase of 34.87%, with a revenue of 80.192 billion yuan, up 90.05% [45] Group 13 - Shenghong Technology achieved a net profit of 2.143 billion yuan, a year-on-year increase of 366.89%, with a revenue of 9.031 billion yuan, up 86.00% [46] - Cambrian achieved a net profit of 1.038 billion yuan, turning a profit, with a revenue of 2.881 billion yuan, up 4347.82% [48] - Longteng Optoelectronics reported a net loss of 121 million yuan, with a revenue of 1.289 billion yuan, down 27.91% [49]

二、监事会会议审议情况 1、审议并通过《关于<公司 2025 年半年度报告>及摘要的议案》 具体内容详见公司在上海证券交易所网站(www.sse.com.cn)披露的《青岛蔚 蓝生物股份有限公司 2025 年半年度报告》及《青岛蔚蓝生物股份有限公司 2025 年半年度报告摘要》。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 青岛蔚蓝生物股份有限公司（以下简称"公司"）第五届监事会第十一次会 议于 2025 年 8 月 27 日在公司会议室以现场表决的方式召开，会议通知已于 2025 年 8 月 17 日以邮件形式发出。本次会议应出席监事 3 人，实际出席 3 人。会议 由公司监事会主席原妤女士主持。会议召集召开程序及审议事项符合《中华人民 共和国公司法》和《青岛蔚蓝生物股份有限公司章程》等有关规定，所形成的决 议合法有效。 证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-036 青岛蔚蓝生物股份有限公司 关于公司第五届监事会第十一次会议决议的公告 表决票：3 票，赞成票：3 票，反对 ...